Kimberly-Clark seeks EU approval for $40 billion Kenvue deal

Kimberly-Clark KMB.O has asked EU regulators permission for its proposed $40 billion takeover of Tylenol maker Kenvue, documents on the EU Commission's website showed.

• Kimberly-Clark announced the takeover in November last year.
• The deal was expected to close in the second half of 2026, it said at the time.
• Kimberly-Clark forecast $2.1 billion in annual cost savings from the deal.
• The addition of Kenvue's vast portfolio of brands from Listerine mouth wash to skincare names like Aveeno and Neutrogena is expected to bring in annual revenues of roughly $32 billion for the combined company, it said.